INVESTIGADORES
KOCHEN Sara Silvia
artículos
Título:
Visual defects associated with vigabatrin: a study of epileptic argentine patients
Autor/es:
MORENO MC, GIAGANTE B, SAIDON P, KOCHEN S, BENOZZI J, ROSENSTEIN RE.
Revista:
Can J Neurol Sci
Editorial:
Canadian Journal Of Neurological Sciences
Referencias:
Año: 2005 vol. 32 p. 459 - 464
Resumen:
Objective: The aim of the present study was to assess visual alterations in a population
of Argentine patients treated with the antiepileptic drug vigabatrin. Methods: Twenty patients receiving
vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a
Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were
performed. Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing.
Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40°
of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform
the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes
of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.The aim of the present study was to assess visual alterations in a population
of Argentine patients treated with the antiepileptic drug vigabatrin. Methods: Twenty patients receiving
vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a
Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were
performed. Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing.
Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40°
of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform
the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes
of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.Methods: Twenty patients receiving
vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a
Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were
performed. Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing.
Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40°
of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform
the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes
of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing.
Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40°
of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform
the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes
of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.
Conclusions: Visual field defects among patients on vigabatrin therapy may occur with a higher
frequency than previously recognized. The Humphrey 120-points full field screening test and
electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.Visual field defects among patients on vigabatrin therapy may occur with a higher
frequency than previously recognized. The Humphrey 120-points full field screening test and
electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.
